Literature DB >> 9755902

Correction for non-ideal tracer pharmacokinetic disposition by disposition decomposition analysis (DDA).

P Veng-Pedersen1, S S Hong, J A Widness, R L Schmidt.   

Abstract

PURPOSE: Pharmacokinetic (PK) studies assume that the tracer's PK is equivalent to the parent compound. This assumption is often violated. The aim of this work is to present a method enabling the ideal tracer PK, i.e. the PK of the parent compound, to be predicted from the non-ideal tracer.
METHODS: The procedure uses a disposition decomposition-recomposition (DDR) that assumes that the labeling mainly changes the elimination kinetics while the distribution kinetics is not significantly affected. In the DDR procedure an elimination rate constant correction factor (kCOR) is determined from a simultaneously fitting to plasma concentration data resulting from an i.v. injection of both the tracer and the parent compound. The correction factor is subsequently used to predict the ideal tracer PK behavior from the disposition function (i.v. bolus response) of the non ideal tracer.
RESULTS: The DDR method when applied to plasma level data of erythropoietin (r-HuEPO) and its iodinated tracer (125I-r-HuEPO) from a high (4000U/kg) and a low (400U/kg) dosing of r-HuEPO in newborn lambs (n=13) resulted in excellent agreements in the elimination rate corrected dispositions in all cases (r=0.995, SD=0.0095). The correction factor did not show a dose dependence (p > 0.05). The correction factors were all larger than 1 (kCOR=1.94, SD=0.519) consistent with a reduction in the EPO elimination by the iodination labeling.
CONCLUSIONS: The DDR tracer correction methodology produces a better differentiation of the PK of endogenously produced compounds by correcting for the non-ideal PK behavior of chemically produced tracers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755902     DOI: 10.1023/a:1011922209757

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

Review 1.  Erythropoietin: structure, control of production, and function.

Authors:  W Jelkmann
Journal:  Physiol Rev       Date:  1992-04       Impact factor: 37.312

2.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Alteration of the pharmacokinetics of small proteins by iodination.

Authors:  R J Bauer; S D Leigh; C A Birr; S L Bernhard; M Fang; K Der; N O Ihejeto; S F Carroll; A H Kung
Journal:  Biopharm Drug Dispos       Date:  1996-12       Impact factor: 1.627

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

5.  Drug absorption evaluation in the presence of changes in clearance: an algorithm and computer program for deconvolution with exact clearance correction.

Authors:  P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  1987 Mar-Apr       Impact factor: 1.627

6.  A computer program for calculating distribution parameters for drugs behaving nonlinearly that is based on disposition decomposition analysis.

Authors:  H Cheng; Y Gong; W J Jusko
Journal:  J Pharm Sci       Date:  1994-01       Impact factor: 3.534

7.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

8.  Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.

Authors:  S T Sawyer; S B Krantz; E Goldwasser
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

9.  Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep.

Authors:  J A Widness; P Veng-Pedersen; N B Modi; R L Schmidt; D H Chestnut
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

10.  A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.

Authors:  J A Widness; R L Schmidt; P Veng-Pedersen; N B Modi; S T Sawyer
Journal:  J Lab Clin Med       Date:  1992-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.